Skip to content

Trial Summary

This is a phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with asymptomatic, untreated melanoma brain metastases.

Acronym:

ABC-X

ACTRN/NCT /ethics:

NCT03340129

Scientific title:

Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (ABC-X)

Sponsor / Cooperative group:

Melanoma Institute Australia

Trial & Patient Characteristics

Cancer TypeMelanoma & other skin
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2019-08-14
Anticipated End Date2025-08-01

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorProfessor Michael Brown
Recruitment StatusRecruiting